FOsfomycin for Male Urinary Tract Infection

Male urinary tract infections (MUTI) are often less recognised compared to those in women. French clinical guidelines practices recommend the use of antibiotics called fluoroquinolones, which are highly effective in treating MUTIs. However, these antibiotics can lead to rare but serious side effects, such as tendonitis or heart rhythm disturbances. Additionally, fluoroquinolones can contribute to the development of bacterial resistance, making their use inadvisable within six months of treatment. In response to these concerns, we aim to explore a well-established alternative, fosfomycin trometamol (known by the brand name MONURIL®). This antibiotic has a strong track record in treating UTIs in women, with well-documented benefits and minimal associated risks. The primary goal of this study is to assess the effectiveness of fosfomycin trometamol in treating urinary tract infections in men, as well as to evaluate any potential treatment failures.

NCT Number	NCT06822751
Lead Sponsor	University Hospital, Rouen Collaborators: INSERM UMR1311 DYNAMICURE, Department of General Practice, Rouen University, Health Ministry funding (ReSpiR funds)
Conditions	Urinary Tract Infection, Prostatitis, Cystitis
Enrollment	138 participants
Start Date	2026-07
Primary Completion	2029-10 (estimated)
Study Completion	2029-10 (estimated)
Updated on ClinicalTrials.gov	2026-06-12